Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Salvage Therapy Of Little Help In Esophageal Ca

October 22, 2013 By Cole Petrochko

Salvage strategies produced “unimpressive” results in esophageal adenocarcinoma patients with locoregional failure after preoperative chemoradiation, researchers found.

Following chemoradiotherapy with subsequent trimodality therapy including surgery, 36 percent of esophageal adenocarcinoma patients experienced distant metastases with or without locoregional failure, most of which (89 percent) occurred within 36 months of surgery, according to Jaffer Ajani, MD, of the University of Texas MD Anderson Cancer Center in Houston, and colleagues.

Of the 5 percent of patients who experienced locoregional failure following treatment, only five of 12 who underwent salvage chemotherapy survived more than 2 years, three of whom developed distant metastases, they wrote online in the Journal of Clinical Oncology.

“Thus, only 2 percent of all 518 patients benefited from surveillance/salvage strategies,” they pointed out.

This new data seems to contradict a study presented at the 2013 Gastrointestinal Cancers Symposium, which showed surgery after chemoradiotherapy was associated with significant increases in 5-year overall survival (OS) compared with patients who received chemotherapy only in patients with advanced esophageal cancer.

Prior research has also shown that preoperative therapy doesn’t benefit patients in early esophageal cancer, nor does endoscopy offer improved survival benefit in patients with esophageal adenocarcinoma.

“After [trimodality therapy], patients are surveyed by various schedules and tests … the primary reason to survey patients after successful local therapy … is to implement a potentially beneficial salvage therapy to overcome locoregional failure,” Ajani’s group explained. “The purpose of this study was to analyze a large cohort of patients who had [trimodality therapy] and to assess the outcome of patients for whom salvage therapy was implemented following locoregional failure.”

Continue reading…

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A portrait of Stryker executive Tracy Robertson
Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
gBETA Medtech accelerator picks its next startups
Titan Medical
Titan Medical inks a $2.6M purchase order from Medtronic

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech